Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201603-02 Development of therapeutic antibody for Alzheimer's disease(CNS Diseases, Protein) [09.02.2016]

PRINT

Development and Market Objectives

1. Discover the lead antibody which inhibits a factor of reactive gliosis caused by nerve damage or degenerative brain diseases.


2. Confirm the therapeutic effects of lead antibody using neuronal cell culture and Alzheimer`s disease animal model.


3. Verify the clinical valuation of glial scar inhibitory mechanism and develop the first-in-class medication of Alzheimer`s disease.

Unmet Medical Need & Target Patients

1. Target patients
Entering into global aging society, geriatric patients are growing rapidly, Especially dementia patients. Expert organizations, such as Ministry of Health and Welfare and Alzheimer`s Association, suggest that more than 2.7 million Koreans and 130 million people in the world may have Alzheimer`s disease by 2050.

 

2. Unmet Medical need
Until now only two Alzheimer`s disease medications, acetylcholinesterase inhibitor and NMDA receptor blocker, have been developed, which lead only to symptomatic improvement and have little effect on disease progression. Recently some amyloid-beta aggregation inhibitors have been developed, but clinical trial results are not able to meet the expectations. There has been tremendous demands for new Alzheimer`s disease medication to delay neurodegeneration. Also, market needs of Alzheimer`s disease medications are expected to increase because of demographic changes such as expanding of aged population.

Status

1. Confirmed the involvement of gliosis in Alzheimer`s disease mice model (APP/Psen1 TG mice) than normal mice model.


2. Confirmed considerable reducing of gliosis in Alzheimer`s disease mice model with injection of monoclonal lead antibody that specifically neutralizing the gliosis-inducing novel ligand.


3. Confirmed reduction of inflammatory markers in microenvironment around amyloid-beta plaque by injection of the monoclonal lead antibody that specifically neutralizing the gliosis-inducing novel ligand.

Intellectual Property

Non-disclosure

Competitive Advantages

Numerous approaches including targeting Amyloid-beta metabolism or delaying neuronal death for the development of novel Alzheimer`s disease treatment have failed to meet primary endpoints in countless clinical trials. This fact indicates that innovative strategies are needed such as focusing on “modulation of neuronal microenvironment (glia)” rather than “protection or regeneration of neurons”.

The previous data show that the novel antibody drug which inhibits gliosis could delay degeneration of neurons and ultimately the progress of Alzheimer’s disease. It is expected that this therapeutic antibody could satisfy the imminent unmet medical needs for the treatment of Alzheimer’s disease, which will guarantee high possibility of global licensing-out.

Indication

Alzheimer

Research Period

Aug. 1, 2016 ~ Jan. 31, 2018

Company

Neuracle Science

Developmental Stage

Generation

Additional Information

Contact Information

Contact
Address Company Name: Neuracle Science
WebSite Homepage: http:// Contact Person: Kim, Bongcheol(CEO), Jeong, Jihyeon(BD Manager)
E-mail: bkim@neuracles.com / biochem@neuracles.com Contact: 02-6409-0409

Related Projects

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code